Prevalence and Antibiotic Resistance of Among STI Clinic Attendees in Western Canada: a Cross-sectional Analysis
Overview
Authors
Affiliations
Objectives: To determine the prevalence and correlates of (MG) infection among men and women, determine the prevalence of gene mutations conferring resistance and compare test performance of female specimen types.
Methods: A cross-sectional study was conducted on specimens collected for gonorrhoea (NG, ) and chlamydia (CT, ) among male and female Alberta STI clinic attendees using the transcription-mediated amplification-research use only test. Positive specimens were sequenced for 23SrRNA, and genes. Gender-stratified analysis compared test results using χ or Fisher's exact test, Mann-Whitney U test and logistic regression. Female endocervical and urine specimens were compared.
Results: A total of 2254 individuals were tested; 53.8% (n=1212) were male. Male prevalence of MG was 5.3%; CT was 5.9% and NG was 1.8%. Correlates of male infection were a non-gonococcal urethritis diagnosis and NG coinfection. MG prevalence for women was 7.2%; CT was 5.8% and NG was 1.8%. Correlates of female infection were younger age, Indigenous/Other ethnicity and CT/NG coinfection. Nearly two-thirds of eligible specimens had mutations associated with macrolide resistance and 12.2% of specimens had a mutation signifying possible moxifloxacin resistance. There was high concordance (98.1%) of results between urine and endocervical swabs.
Conclusions: The high prevalence of MG relative to CT and NG supports the incorporation of MG testing into routine sexually transmissible infection screening. The high rate of resistance to macrolides and moxifloxacin raises concerns about treatment options. The good concordance of results between urine and endocervical swabs supports the use of female urine specimens for testing.
infection among gay, bisexual and other men who have sex with men in Montréal, Canada.
Le A, Labbe A, Fourmigue A, Dvorakova M, Cox J, Fortin C Can Commun Dis Rep. 2024; 49(11-12):477-486.
PMID: 38504874 PMC: 10946590. DOI: 10.14745/ccdr.v49i1112a03.
Salgado V, de Abreu Oliveira C, da Silva A, Brito H, de Medeiros D, Soares F BMC Infect Dis. 2023; 23(1):244.
PMID: 37072756 PMC: 10114492. DOI: 10.1186/s12879-023-08213-z.
Kato H, Hagihara M, Asai N, Hirai J, Yamagishi Y, Iwamoto T Antibiotics (Basel). 2022; 11(3).
PMID: 35326816 PMC: 8944501. DOI: 10.3390/antibiotics11030353.
Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for Spp. and .
Spiller-Boulter O, Paukner S, Boostrom I, Sands K, Portal E, Spiller O Antibiotics (Basel). 2021; 10(11).
PMID: 34827308 PMC: 8614837. DOI: 10.3390/antibiotics10111370.
Lannoy L, Silva R, Nahn Junior E, Oliveira E, Gaspar P Rev Soc Bras Med Trop. 2021; 54(suppl 1):e2020633.
PMID: 34008729 PMC: 8210486. DOI: 10.1590/0037-8682-633-2020.